Home
News
Create
Screeners
Insights
ANG Lifesciences
30.
00
+0.31
(+1.04%)
Market Cap
₹39.21 Cr
PE Ratio
-3.50
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.04%
1M
+9.05%
6M
+1.04%
1Y
-0.99%
5Y
-59.24%
View Company Insights
Latest news about ANG Lifesciences
ANG Lifesciences narrows FY26 loss to ₹1,108 lakh
10 days ago
ANG Lifesciences India Limited reported a narrowed consolidated net loss of ₹1,108.48 lakh for FY26, with revenue from operations rising marginally to ₹9,289.28 lakh. The standalone net loss improved to ₹472.64 lakh. Statutory auditors M/s Khurana Sharma & Company issued an unmodified opinion but highlighted defaults on HDFC Bank borrowings totaling ₹1,344.16 lakh standalone and ₹2,586.45 lakh consolidated, alongside unpaid statutory dues exceeding six months. The company operates in Pharmaceuticals and Printing and Packaging segments.
ANG Lifesciences schedules board meeting on May 30
May 22, 2026
ANG Lifesciences India Limited Confirms Non-Applicability of SEBI Large Corporate Borrowing Requirements for FY26
Apr 17, 2026
ANG Lifesciences India Limited Submits SEBI Compliance Certificate for Q4 FY26
Apr 15, 2026
ANG Lifesciences India Limited Responds to BSE Query on Recent Price Movement
Apr 10, 2026
More news about ANG Lifesciences
15
Feb 26
ANG Lifesciences Reports Q3 FY26 Financial Results with Detailed Performance Metrics
ANG Lifesciences India Limited reported Q3 FY26 financial results showing revenue growth in standalone operations to ₹2,597.05 lakhs from ₹2,390.85 lakhs year-over-year, though nine-month revenue declined to ₹6,880.44 lakhs from ₹7,224.40 lakhs. The company operates through pharmaceuticals and printing segments with consolidated results approved by the Board on February 14, 2026.
05
Feb 26
ANG Lifesciences India Limited Schedules Board Meeting for February 14, 2026 to Consider Q3FY26 Financial Results
ANG Lifesciences India Limited has scheduled a board meeting for February 14, 2026, at 05:00 P.M. to consider and approve unaudited financial results for Q3FY26 and nine months ended December 31, 2025. The meeting will be held at the company's registered office in Amritsar. A trading window closure is in effect from January 1, 2026, until 48 hours after results publication, in compliance with SEBI insider trading regulations.
15
Nov 25
ANG Lifesciences Reports Q2 FY2026 Loss, Appoints New Cost Auditor
ANG Lifesciences India Limited reported a reduced net loss of ₹79.98 lakh in Q2 FY2026, down from ₹107.39 lakh in Q2 FY2025. However, revenue from operations decreased to ₹2597.05 lakh from ₹3215.88 lakh year-over-year. For H1 FY2026, the net loss improved to ₹158.71 lakh from ₹383.92 lakh in the previous year. The company's Board approved the appointment of M/s Shreya Sahu & Associates as Cost Auditor for FY2025-26.
ANG Lifesciences
30.
00
+
0.
31
(+
1.
04
%)
1 Year Returns:
-0.99%
Industry Peers
Sun Pharmaceutical
1,779.00
(-
0.
55
%)
Divis Laboratories
6,753.00
(+
3.
56
%)
Torrent Pharmaceuticals
4,472.90
(+
1.
42
%)
Zydus Life Science
1,105.60
(+
1.
66
%)
Cipla
1,376.50
(-
0.
82
%)
Dr Reddys Laboratories
1,268.50
(-
0.
56
%)
Lupin
2,264.20
(+
0.
43
%)
Mankind Pharma
2,391.00
(+
1.
43
%)
Aurobindo Pharma
1,449.00
(-
0.
19
%)
Laurus Labs
1,424.40
(+
1.
40
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar